康惠尔水胶体敷料应用于静脉炎的效果观察

目的：为了有效治疗静脉炎,为临床提供参考。方法：对采用康惠尔水胶体敷料外敷与土豆片外敷治疗静脉炎的疗效进行比较。结果：康惠尔水胶体敷料外敷治疗静脉炎的疗效好于土豆片外敷,操作方法简便,安全有效,病人活动不受限制。结论：康惠尔水胶体敷料应用于治疗静脉炎疗效好。     

Neuroimaging Findings in Intracranial Sarcoid Phlebitis: A Case Report

Introduction

Venous phlebitis in Neurosarcoidosis (NS) is rare but is often associated with intracranial hemorrhage (ICH). Imaging findings in such cases have been recently described on susceptibility weighted imaging (SWI).

延胡索合剂治疗化疗性静脉炎的效果观察

目的观察延胡索合剂（YHS-1）对化疗性静脉炎的防护作用。方法选取80例由外周静脉输注化疗药物后引起不同程度静脉炎的患者。随机分为观察组和对照组,其中观察组于病变局部外敷YHS-1,对照组于病变局部外敷如意金黄散,观察静脉炎及疼痛程度与恢复时间。结果 YHS-1外敷治疗化疗性静脉炎的效果优于如意金黄散,且治愈疼痛的效果显著,其疼痛持续时间小于如意金黄散组。结论 YHS-1对化疗药物引起的静脉炎和静脉损伤有防治作用,应尽早应用。     

乳酸依沙吖啶联合金黄散治疗化学性静脉炎的疗效观察

目的观察乳酸依沙吖啶溶液联合金黄散治疗化学性静脉炎的疗效观察。方法选取本院2015年6月-2017年12月肿瘤化疗发生静脉炎患者46例作为研究对象,随机分成两组。对照组:采用50%的硫酸镁湿热敷患处。观察组:采用乳酸依沙吖啶溶液与金黄散制剂交替湿热敷患处。3天后利用疼痛评估量表与静脉炎分级标准结合进行评价。结果观察组治愈23例,显效18例,总有效率95.65%,有统计意义(P<0.01)。结论乳酸依沙吖啶溶液联合金黄散治疗化学性静脉炎不但有良好的治疗效果,而且实用、无毒副作用。     

凉血通脉膏护理化疗性静脉炎的临床护理效果

目的 评价凉血通脉膏护理化疗性静脉炎的临床护理效果。方法 选择某医院2017年4月—2018年11月化疗性静脉炎患者100例。随机分组,常规护理组采取化疗性静脉炎常规护理,联合护理组则采取常规护理联合凉血通脉膏护理。比较两组患者的化疗性静脉炎治疗效果。结果 联合护理组治疗总有效率为98%,高于常规护理组的78%(P<0.05)。联合护理组静脉条索消失的时间、局部红肿消失的时间、局部疼痛消失的时间分别为(4.45±1.02)d、(4.24±1.21)d、(4.11±1.04)d,均短于常规护理组(P<0.05)。联合护理组并发症发生率为2%,低于常规护理组的14%(P<0.05),联合护理组并发症发生率是2%,而常规护理组并发症发生率为14%。结论 联合护理对于化疗性静脉炎治疗效果确切,可加速症状消失和减少并发症。     

利用实时细胞分析技术检测胰腺癌细胞的药物敏感性

目的基于实时细胞分析技术评估胰腺癌细胞的药物敏感性,为胰腺癌个体化诊疗提供参考。方法选取SW1900、Capan-2、PANC-1三株人胰腺癌细胞系,选用盐酸吉西他滨和替吉奥胶囊两种胰腺癌治疗药物,接种24 h后分别梯度浓度给药,实时细胞分析技术监测给药前后细胞生长曲线,计算药物对胰腺癌细胞的生长抑制率(IC50)。同时,细胞培养板内给药,进行AO/EB染色和激光共聚焦观察。结果药物作用72 h,同一药物对不同细胞抑制率不同。盐酸吉西他滨对SW1900、Capan-2、PANC-1细胞的IC50分别为1.69、10.05、12.74μmol/L。替吉奥胶囊对SW1900、Capan-2、PANC-1细胞的IC50分别为180.29、765.70、95.57μmol/L。AO/EB染色验证IC50真实可靠。结论 SW1900及Capan-2细胞可作为盐酸吉西他滨及替吉奥的对照,建立细胞模型,对药物进行体外筛选,为临床利用该技术进行病人肿瘤药物筛选提供一个参考,具有一定的借鉴意义。     

自制地塞米松乳膏预防盖诺所致迟发性过敏性静脉炎的疗效观察

目的:观察自制地塞米松乳膏外涂及静脉输注地塞米松预防盖诺所致迟发性过敏性静脉炎的疗效。方法:对62例使用盖诺396例次的肿瘤患者按用药的先后顺序随机分为两组,观察组采用静脉输注盖诺前后分别给予生理盐水100 ml加地塞米松5 mg静脉输注,在使用盖诺前2 min～3 min,沿着穿刺静脉周围5 cm～10 cm范围内涂抹地塞米松乳膏。对照组采用静脉输注盖诺前后分别给予生理盐水100 ml加地塞米松5 mg静脉输注,观察两组迟发性静脉炎的发生率。结果:观察组迟发性过敏性静脉炎发生率(4.2%)明显低于对照组(35.0%),P<0.01。结论:配合外用地塞米松乳膏预防盖诺所致迟发性过敏性静脉炎的效果优于单用地塞米松法。     

Photosensitive pro-drug nanoassemblies harboring a chemotherapeutic dormancy function potentiates cancer immunotherapy

Immunotherapy combined with effective therapeutics such as chemotherapy and photodynamic therapy have been shown to be a successful strategy to activate anti-tumor immune responses for improved anticancer treatment. However, developing multifunctional biodegradable, biocompatible, low-toxic but highly efficient, and clinically available transformed nano-immunostimulants remains a challenge and is in great demand. Herein, we report and design of a novel carrier-free photo-chemotherapeutic nano-prodrug COS-BA/Ce6 NPs by combining three multifunctional components—a self-assembled natural small molecule betulinic acid (BA), a water-soluble chitosan oligosaccharide (COS), and a low toxic photosensitizer chlorin e6 (Ce6)—to augment the antitumor efficacy of the immune adjuvant anti-PD-L1-mediated cancer immunotherapy. We show that the designed nanodrugs harbored a smart and distinctive “dormancy” characteristic in chemotherapeutic effect with desired lower cytotoxicity, and multiple favorable therapeutic features including improved ¹O₂ generation induced by the reduced energy gap of Ce6, pH-responsiveness, good biodegradability, and biocompatibility, ensuring a highly efficient, synergistic photochemotherapy. Moreover, when combined with anti-PD-L1 therapy, both nano-coassembly based chemotherapy and chemotherapy/photodynamic therapy (PDT) could effectively activate antitumor immunity when treating primary or distant tumors, opening up potentially attractive possibilities for clinical immunotherapy.     

反义bcl-2基因转染对单核白血病细胞存活及化疗耐受能力的影响

目的：探讨ｂｃｌ－２反义核酸在单核白血病细胞系Ｕ９３７细胞中的作用,以丰富ｂｃｌ－２及其反义核酸调控肿瘤细胞凋亡的资料。方法：将反义ｂｃｌ－２基因表达载体ｐＬＸＳＮ／ａｓ－ｂｃｌ－２转染于Ｕ９３７细胞,建立Ｕ９３７／ａｓ－ｂｃｌ－２细胞模型,利用流式细胞技术模型细胞ｂｃｌ－２的表达水平。通过细胞计数观察模型细胞在正常培养条件下和有化疗药物Ａｒａ－Ｃ或三     

Endothelial cell compatibility of clarithromycin for intravenous use

Objectives: Tolerance of intravenously applied clarithromycin has been tested on marginal ear veins of rabbits. Use of human umbilical venous endothelial cells (HUVEC) for testing antibiotic solutions for intravenous compatibility provides a valuable alternate model.

Design and methods: In order to evaluate the effect of clarithromycin on intracellular purines, reflecting cell viability, energy production, signal transduction and DNA/RNA synthesis, intracellular adenosine 5’ triphosphate (ATP), adenosine 5’ diphosphate (ADP), guanosine 5’ triphosphate (GTP), and guanosine 5’ diphosphate (GDP) levels were measured by means of high performance liquid chromatography (HPLC).

Results: Incubation of cells with 2 mg/mL clarithromycin resulted in a rapid decrease of the intracellular ATP from 12.6 ± 1.1 to 8.87 ± 0.82 nmol/million cells or 1.5 ± 0.6 nmol/million cells, after 20 or 60 min, respectively. In addition, ADP was extensively depleted. Purine nucleotide profiles were markedly different following exposure to 1 mg/mL clarithromycin. There was no significant decline of intracellular high energy phosphate levels after 20 min.

Conclusion: These results show that clarithromycin has a better endothelial compatibility if diluted to a final concentration of 1 mg/mL. These data are in line with our clinical observations that the occurrence of phlebitis could be minimized by diluting the manufacturers’ preparation of clarithromycin to 1 mg/mL.